Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment

[1]  S. Meshnick,et al.  Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial , 2017, PloS one.

[2]  Richard J Maude,et al.  Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study , 2017, The Lancet. Global health.

[3]  N. White.  Does antimalarial mass drug administration increase or decrease the risk of resistance? , 2017, The Lancet. Infectious diseases.

[4]  A. Dicko,et al.  Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. , 2016, The Lancet. Infectious diseases.

[5]  T. Bousema,et al.  Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial , 2016, BMC Medicine.

[6]  Thomas Smith,et al.  Consensus modelling evidence to support the design of mass drug administration programmes: A report by the Malaria Modelling Consortium (MMC) for the Malaria Policy Advisory Committee (MPAC), World Health Organization, 16–18 September 2015, Geneva, Switzerland, Background document for Session 1 , 2015 .

[7]  Kwaku Poku Asante,et al.  Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa , 2015, Malaria Journal.

[8]  Jaline Gerardin,et al.  Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination , 2015, BMC Infectious Diseases.

[9]  Jamie T. Griffin,et al.  The Interaction between Seasonality and Pulsed Interventions against Malaria in Their Effects on the Reproduction Number , 2015, PLoS Comput. Biol..

[10]  R. Price,et al.  Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria , 2014, Malaria Journal.

[11]  A. Ghani,et al.  Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis , 2014, Nature Communications.

[12]  E. Ashley,et al.  Primaquine: the risks and the benefits , 2014, Malaria Journal.

[13]  Xavier C Ding,et al.  Defining the biology component of the drug discovery strategy for malaria eradication. , 2014, Trends in parasitology.

[14]  Neil M. Ferguson,et al.  Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa , 2014, Nature Communications.

[15]  David L. Smith,et al.  Modeling Within-Host Effects of Drugs on Plasmodium falciparum Transmission and Prospects for Malaria Elimination , 2014, PLoS Comput. Biol..

[16]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[17]  R. Sinden,et al.  Male and Female Plasmodium falciparum Mature Gametocytes Show Different Responses to Antimalarial Drugs , 2013, Antimicrobial Agents and Chemotherapy.

[18]  N. White.  Primaquine to prevent transmission of falciparum malaria. , 2013, The Lancet. Infectious diseases.

[19]  N. Maire,et al.  Modeling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden , 2012, Malaria Journal.

[20]  Richard J. Maude,et al.  Optimising Strategies for Plasmodium falciparum Malaria Elimination in Cambodia: Primaquine, Mass Drug Administration and Artemisinin Resistance , 2012, PloS one.

[21]  Arantxa Roca-Feltrer,et al.  Estimating the potential public health impact of seasonal malaria chemoprevention in African children , 2012, Nature Communications.

[22]  N. Maire,et al.  The distribution of Plasmodium falciparum infection durations. , 2011, Epidemics.

[23]  T. Déirdre Hollingsworth,et al.  The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria , 2011, PloS one.

[24]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[25]  Wes Hinsley,et al.  Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies , 2010, PLoS medicine.

[26]  Teun Bousema,et al.  Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs , 2010 .

[27]  David L. Smith,et al.  Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations , 2009, Malaria Journal.

[28]  Paul Garner,et al.  Artemisinin-based combination therapy for treating uncomplicated malaria. , 2009, The Cochrane database of systematic reviews.

[29]  A. Ghani,et al.  Modelling the Impact of Artemisinin Combination Therapy and Long-Acting Treatments on Malaria Transmission Intensity , 2008, PLoS medicine.

[30]  Thomas A. Smith,et al.  An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-saharan Africa. , 2006, The American journal of tropical medicine and hygiene.

[31]  N. Maire,et al.  Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. , 2006, The American journal of tropical medicine and hygiene.

[32]  Petra Schneider,et al.  Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. , 2006, The Journal of infectious diseases.

[33]  G. Killeen,et al.  Estimating the duration of Plasmodium falciparum infection from trials of indoor residual spraying. , 2004, The American journal of tropical medicine and hygiene.

[34]  N. White,et al.  The evolution of drug-resistant malaria: the role of drug elimination half-life. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[35]  A. Blanc.  Demographic and health surveys , 1991 .

[36]  K. Rieckmann,et al.  Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. , 1968, Bulletin of the World Health Organization.